Solesence (NANX): Restatement Shakes Q2, but Scalp Care and a Record Backlog Signal a Transformational Second Half
On its Q2 2026 call, Solesence (NANX) faced a familiar yet serious challenge: a restatement of inventory costing that dragged its financials into the red. Yet management pivoted quickly to a growth narrative—scalp care launches, a record order backlog, and the promise of double-digit growth. The juxtaposition of accounting discipline and commercial momentum is what makes this call worth reading.
Inventory Restatement: A Legacy Issue, Not a Cash Problem
Kevin Cureton opened with a strong commitment to integrity, acknowledging the gravity of the Net tariff refunds mess—well, not tariffs, but the inventory costing issue. Laura Riffner detailed the root cause: “During our quarter-end review, we identified an issue with our historical inventory costing methodology regarding how indirect manufacturing costs were allocated to inventory. Working closely with our advisors, we have completed our evaluation and are implementing the necessary restatements to correct this inventory valuation issue.” — Laura Riffner, Chief Financial Officer · 2026-08-19 She emphasized repeatedly that the adjustments have no cash impact:
The financials for the quarter reflect the pain: revenue fell to $15.3 million from $20.4 million a year ago (a 25% drop), gross margin slipped to 31% from 32%, and the company swung to a net loss of $158,000 from a $3.2 million profit, with adjusted EBITDA at a meager $523,000 versus $3.7 million. But executives were quick to note that the prior-year period had benefited from a major product launch and pipeline fill, and that reorders and forecasts for that product are improving.The adjustments relate to the accounting for certain costs within inventory and do not affect the underlying cash generated or used by the business, our day-to-day operations, or our ability to serve our brand partners.
The Growth Engine: Scalp Care and BEMT
The call’s most forward-looking moment came when Kevin described the newly launched scalp care line, an adjacency that management clearly hopes will drive launch readiness and diversification. “the scalp care segment is a new segment for us. We launched this year, in fact, just back in July, utilizing some of our new technologies. That market is an area where we approximately believe it's about a $3 billion addressable market for what we do.” — Kevin Cureton, President and Chief Executive Officer · 2026-08-19 He also touched on the FDA’s approval of a non-mineral sunscreen platform (BEMT), which he sees as complementary rather than threatening to Solesence’s proprietary mineral-based technologies. The company is already planning combination products—a theme that resonates with the broader industry shift toward ingredient blending and performance boosting.
Confluence with Sector Themes: Tariff Refunds and Inventory Reliability
Solesence’s inventory restatement comes at a time when the consumer-staples complex is under intense scrutiny over inventory accuracy and cost controls. Retailers like Target (TGT) have highlighted Inventory reliability as a key metric, and many companies across the sector are benefiting from IEEPA tariff refund—a theme notably absent from Solesence’s call, suggesting it is not a tariff-exposed player but still must manage input costs. The contrast is instructive: while peers reap one-time refunds and optimize inventory via advanced systems, Solesence is still remediating a legacy costing method that management admits stemmed from “how this business was grown and managed in the past.”
Recurring Operational Woes but a Confident Outlook
This is not the first time Solesence has fielded investor frustration over operations. On the May 2026 call, Kevin acknowledged “first quarter was primarily impacted by our OTIF performance, On-Time and In-Full performance, which was impacted by some of the changes in our processes during Q1 that we expect to really deliver on improved results through the remainder of the year.” — Kevin Cureton, President and Chief Executive Officer · 2026-05-12 A year earlier, he’d already promised to fix inventory: “Specifically around inventory management, that is an area that has taken us more time than we would like to repair. But with the changes that we've made, we're confident that we're on the right path to fixing that issue.” — Kevin Carrington, CEO · 2025-11-11 The latest call echoes that confidence, now backed by a concrete order book: $64.9 million in shipped and on-hand orders as of August 17, up from $60 million at the same point in 2025. Management projects second-half revenue of ~$35 million, the strongest in company history, and expects to outgrow 2025 on a full-year basis.
For a micro-cap like Solesence, the restatement is a black mark, but the underlying commercial momentum—new launches, a record pipeline, and a focus on operational excellence—suggests the company is approaching an inflection. Investors will watch whether the recovery extends beyond the order backlog into sustained profitability, but the tone of this call gives reason to believe the turnaround is underway.